Selective activators of the mGluR5 subtype metabotropic glutamate receptor (mGluR) have been proposed as a novel approach for treatment of schizophrenia. Unfortunately, previous efforts to develop highly selective mGluR5 agonists have failed because of the high conservation of the orthosteric glutamate binding site across all mGluR subtypes. We have now developed highly selective activators of mGluR5 that have no activity at any other mGluR subtype. The key to achieving this unprecedented selectivity was to target allosteric sites on mGluR5 rather than developing traditional agonists acting at the highly conserved glutamate binding site. The prototypical mGluR5 positive allosteric modulators (PAMs) do not activate mGluR5 directly but potentiate the response of the receptor to glutamate. These mGluR5 PAMs potentiate mGluR5-mediated responses in multiple neuronal populations and our preliminary studies suggest that mGluR5 PAMs have activity in rodent models that are used to predict antipsychotic efficacy. In addition, we have shown that mGluR5 PAMs enhance hippocampal synaptic plasticity and our preliminary studies reveal that mGluR5 PAMs enhance at least one form of hippocampal-dependent learning in rodents. These studies suggest that mGluR5 PAMs may provide efficacy in treatment of both positive symptoms and cognitive disturbances in schizophrenia patients. We have now discovered a range of structurally and functionally distinct mGluR5 PAMs that have excellent pharmacokinetic profiles and brain penetration for use in behavioral studies. In addition, we have developed mGluR5 PAMs that have distinct modes of efficacy. These include the prototypical pure allosteric potentiators that have no effects in the absence of glutamate, and other compounds that have allosteric agonist activity and fully activate mGluR5 in the absence of glutamate. It is possible that these new mGluR5 allosteric agonist/potentiators will have advantages or disadvantages to pure allosteric potentiators in vivo. However, at present, allosteric agonist activity has only been established in recombinant systems and it is not clear whether allosteric agonist activity will be observed when measuring multiple functional responses to mGluR5 activation in native systems. Also, the effects of mGluR5 PAMs that have these two modes of efficacy (pure potentiators versus allosteric agonist/potentiators) have not been rigorously evaluated in a broad range of animal models designed to assess potential antipsychotic activity and efficacy in improving different domains of cognitive function. Thus, we will perform a series of studies to systematically test the hypothesis that these novel compounds regulate mGluR5 signaling in brain circuits thought to be important for their potential therapeutic effects. In addition, we will test the hypothesis that mGluR5 PAMs have efficacy in a range of animal models that predict antipsychotic and cognition-enhancing effects and will directly compare the effects of pure allosteric potentiators versus mGluR5 allosteric agonist/potentiators.

Public Health Relevance

Studies in patients suffering from the schizophrenia suggest that drugs that selectively activate a specific receptor for the neurotransmitter glutamate may provide a novel approach for treatment of this debilitating brain disorder. We have discovered new drug like molecules that selectively activate this neurotransmitter receptor. Studies are proposed to test the hypothesis that these novel molecules have actions that predict efficacy in treatment of schizophrenia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH062646-13
Application #
8214541
Study Section
Molecular Neuropharmacology and Signaling Study Section (MNPS)
Program Officer
Nadler, Laurie S
Project Start
2001-02-15
Project End
2016-01-31
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
13
Fiscal Year
2012
Total Cost
$437,426
Indirect Cost
$157,025
Name
Vanderbilt University Medical Center
Department
Pharmacology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
O'Brien, Daniel E; Conn, P Jeffrey (2016) Neurobiological Insights from mGlu Receptor Allosteric Modulation. Int J Neuropsychopharmacol 19:
Lindsley, Craig W; Emmitte, Kyle A; Hopkins, Corey R et al. (2016) Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. Chem Rev 116:6707-41
Gregory, Karen J; Velagaleti, Ranganadh; Thal, David M et al. (2016) Clickable Photoaffinity Ligands for Metabotropic Glutamate Receptor 5 Based on Select Acetylenic Negative Allosteric Modulators. ACS Chem Biol 11:1870-9
Conde-Ceide, Susana; Alcázar, Jesús; Alonso de Diego, Sergio A et al. (2016) Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Bioorg Med Chem Lett 26:429-34
Sengmany, Kathy; Singh, Junaid; Stewart, Gregory D et al. (2016) Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery. Neuropharmacology :
Nickols, Hilary Highfield; Yuh, Joannes P; Gregory, Karen J et al. (2016) VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy. J Pharmacol Exp Ther 356:123-36
Ghoshal, Ayan; Conn, P Jeffrey (2015) The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia. Future Neurol 10:115-128
Malosh, Chrysa; Turlington, Mark; Bridges, Thomas M et al. (2015) Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. Bioorg Med Chem Lett 25:5115-20
Martín-Martín, María Luz; Bartolomé-Nebreda, José Manuel; Conde-Ceide, Susana et al. (2015) Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorg Med Chem Lett 25:1310-7
Walker, Adam G; Conn, P Jeffrey (2015) Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics. Curr Opin Pharmacol 20:40-5

Showing the most recent 10 out of 71 publications